Cardio Diagnostics Holdings (CDIO) Other Operating Expenses (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Other Operating Expenses of $202244.0 for Q1 2026, down 86.27% sequentially from $1.5 million in Q4 2025, and down 13.72% YoY from $234415.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Other Operating Expenses (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Other Operating Expenses for 6 years, with the latest figure at $202244.0 in Q1 2026.
- Quarterly Other Operating Expenses fell 13.72% year-over-year to $202244.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 197.44% YoY) and the FY2025 annual result came in at $832121.0, up 235.93% from the prior year.
- Other Operating Expenses fell to $202244.0 in Q1 2026 per CDIO's latest filing, from $1.5 million in the prior quarter.
- Over five years, Other Operating Expenses peaked at $1.5 million in Q4 2025 and troughed at -$57779.0 in Q2 2024.
- A 5-year average of $164951.9 and a median of $39195.0 in 2024 frame the typical range for Other Operating Expenses.
- The widest YoY moves for Other Operating Expenses: up 2725.1% in 2022, down 11685.14% in 2022.
- Over 5 years, Other Operating Expenses stood at $87339.0 in 2022, then plunged by 60.2% to $34758.0 in 2023, then soared by 1027.64% to $391944.0 in 2024, then soared by 275.9% to $1.5 million in 2025, then sank by 86.27% to $202244.0 in 2026.
- According to Business Quant data, Other Operating Expenses over the past three periods registered $202244.0, $1.5 million, and $234415.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 168,522.00 |
| Mar 31, 2026 | 202,244.00 |
| Dec 31, 2025 | 1.47 Mn |
| Mar 31, 2025 | 234,415.00 |
| Dec 31, 2024 | 391,944.00 |
| Sep 30, 2024 | -5,247.00 |
| Jun 30, 2024 | -57,779.00 |
| Mar 31, 2024 | 39,195.00 |
| Dec 31, 2023 | 34,758.00 |
| Sep 30, 2023 | 43,510.00 |
| Jun 30, 2023 | 17,110.00 |
| Mar 31, 2023 | 91,450.00 |
| Dec 31, 2022 | 87,339.00 |
| Sep 30, 2022 | 20,369.00 |
| Jun 30, 2022 | -45,993.00 |
| Mar 31, 2022 | -52,370.00 |
| Dec 31, 2021 | 20,887.00 |
| Sep 30, 2021 | 721.00 |
| Jun 30, 2021 | 397.00 |